Laekna Therapeutics, a Chinese biotech startup that develops innovative therapeutics to treat cancer and liver diseases, announced on Wednesday the completion of a Series D funding round at $61 million to speed up the clinical trials of its drug pipeline.
The round was led by CMG-SDIC Capital, a private equity (PE) firm co-launched by China’s SDIC Fund Management and China Merchants Capital. Existing shareholder Yanchuang Capital participated in the deal, alongside Wanhui Capital and Infinity Capital.
